UPA Cardarine 10mg (GW-501516)

UPA Cardarine 10mg is listed as containing GW-501516 (Cardarine), an investigational compound classified as a Peroxisome Proliferator-Activated Receptor Delta (PPARδ) agonist. Each pack contains 50 tablets, with a stated strength of 10mg per tablet.

Cardarine was originally developed for research into metabolic disorders, cholesterol regulation and cardiovascular health. It has also attracted interest in fitness communities because of its proposed effects on fat metabolism, endurance and energy utilisation.

Unlike Selective Androgen Receptor Modulators (SARMs), Cardarine does not directly activate androgen receptors and is not classified as an anabolic steroid.

What UPA Cardarine Is Used For

GW-501516 has been investigated for its potential effects on lipid metabolism, energy utilisation and metabolic regulation.

Its primary research areas include:

• Fat Metabolism: Investigated for its ability to influence fatty acid oxidation and the body's utilisation of fats as an energy source.
• Endurance and Stamina: Demonstrated effects on exercise endurance in animal studies, although these benefits have not been established in humans.
• Energy Utilisation: Studied for its influence on metabolic pathways involved in cellular energy production.
• Cholesterol Regulation: Investigated for potential effects on HDL cholesterol, LDL cholesterol and triglyceride levels.
• Metabolic Function: Examined for its influence on glucose and lipid metabolism.
• Muscle Energy Metabolism: Studied for its potential effects on oxidative metabolism in skeletal muscle tissue.
• Body Composition: Has attracted interest for potential fat-loss applications, although meaningful fat-loss benefits have not been clinically established.

How UPA Cardarine Works

Cardarine (GW-501516) works by activating Peroxisome Proliferator-Activated Receptor Delta (PPARδ), a nuclear receptor involved in regulating lipid metabolism, energy balance and metabolic gene expression.

Unlike anabolic steroids and SARMs, Cardarine does not primarily interact with androgen receptors or directly stimulate testosterone-related pathways.

Its primary mechanisms include:

• PPARδ Activation: Activates receptors involved in regulating genes associated with fat metabolism and energy utilisation.
• Fatty Acid Oxidation: Influences metabolic pathways responsible for breaking down fatty acids for energy.
• Energy Metabolism: Affects gene expression associated with cellular energy production.
• Lipid Regulation: Has demonstrated effects on cholesterol and triglyceride metabolism in early clinical research.
• Skeletal Muscle Metabolism: Influences pathways associated with oxidative metabolism in muscle tissue.
• Metabolic Adaptation: Has demonstrated exercise-related metabolic adaptations in animal research.

Possible Side Effects

Cardarine (GW-501516) is an unapproved investigational compound with significant safety concerns. Its long-term effects in humans have not been established.

Common or Recognised Side Effects:

There is insufficient human clinical evidence to establish which adverse effects are common. Documented safety concerns and potential risks include:

• Cancer development observed in multiple organs during animal studies.
• Potential carcinogenic effects associated with prolonged exposure.
• Reproductive toxicity concerns identified in safety assessments.
• Unknown long-term effects on human metabolic regulation.
• Potential adverse effects associated with prolonged PPARδ activation.
• Unpredictable health effects due to insufficient long-term human safety data.